Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 2058-2063

  Chabot, John A ^a   Tsai, Wei Yann ^a   Fine, Robert L ^a   Chen, Chunxia ^a   Kumah, Carolyn K ^a   Antman, Karen A ^a   Grann, Victor R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; GEMCITABINE; PANCREAS ENZYME; PROTEINASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PEPTIDE HYDROLASE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; DETOXIFICATION; ENZYME THERAPY; FEMALE; HUMAN; INOPERABLE CANCER; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ADENOCARCINOMA; AGED; ALTERNATIVE MEDICINE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENTARY THERAPIES; DEOXYCYTIDINE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDE HYDROLASES; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951629653     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.8429     Document Type: Article

References (45)

1. Ries L, Malbert D, Krapcho M, et al: Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975-2005 (of November 2007 SEER data submission), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/ csr/1975-2005/
2. Gonzalez NJ: Enzyme Therapy and Cancer. http://www.dr-gonzalez.com/ history-of-treatment.htm
3. Gonzalez NJ, Isaaacs LL: Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 33:117-124, 1999 (Pubitemid 29269997)
4. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
5. Burris HA 3rd: Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 32:S1-S3, 2005 (suppl 6)
6. El-Rayes BF, Philip PA: A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol 1:430-434, 2003
7. Tempero M, Plunkett W, Ruiz Van Haperen V, et al: Randomized phase II comparison of doseintense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003 (Pubitemid 46594072)
8. Fine R, Fogelman D, Sherman JW, et al: The GTX regimen: A biochemically synergistic combination for advanced pancreatic cancer (PC). J Clin Oncol 22:281s, 2003 (suppl; abstr 1129)
9. Fogelman DR, Chen J, Chabot JA, et al: The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: From 5-fluorouracil to GTX. Surg Oncol Clin N Am 13:711-735, 2004 (Pubitemid 39213983)
10. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
11. Rosenbaum PR, Rubin DB: The bias due to incomplete matching. Biometrics 41:103-116, 1985
12. Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual Life Res 11:207-221, 2002 (Pubitemid 34553502)
13. Wong GY, Schroeder DR, Carns PE, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA 291:1092-1099, 2004 (Pubitemid 38541686)
14. Kelsen DP, Portenoy RK, Thaler HT, et al: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 13:748-755, 1995
15. Nahleh Z, Tabbara IA: Complementary and alternative medicine in breast cancer patients. Palliat Support Care 1:267-273, 2003
16. Yates JS, Mustian KM, Morrow GR, et al: Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806-811, 2005 (Pubitemid 41414021)
17. Jacobson JS, Workman SB, Kronenberg F: Research on complementary/ alternative medicine for patients with breast cancer: A review of the biomedical literature. J Clin Oncol 18:668-683, 2000 (Pubitemid 30078549)
18. Small EJ, Frohlich MW, Bok R, et al: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595-3603, 2000
19. Sovak M, Seligson AL, Konas M, et al: Herbal composition PC-SPES for management of prostate cancer: Identification of active principles. J Natl Cancer Inst 94:1275-1281, 2002
20. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029-1035, 1994
21. Evans M, Shaw A, Thompson EA, et al: Decisions to use complementary and alternative medicine (CAM) by male cancer patients: Information-seeking roles and types of evidence used. BMC Complement Altern Med 7:25, 2007
22. Xu L, Lao LX, Ge A, et al: Chinese herbal medicine for cancer pain. Integr Cancer Ther 6:208-234, 2007 (Pubitemid 47301116)
23. Antman K, Benson MC, Chabot J, et al: Complementary and alternative medicine: The role of the cancer center. J Clin Oncol 19:55S-60S, 2001
24. Soares HP, Kumar A, Daniels S, et al: Evaluation of new treatments in radiation oncology: Are they better than standard treatments? JAMA 293:970-978, 2005
25. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887-1892, 2000
26. Preventive Services Task Force: Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. (ed 2). Baltimore, MD, Williams and Wilkins, 1996
27. Grann A, Grann VR: The case for randomized trials in cancer treatment: New is not always better. JAMA 293:1001-1003, 2005 (Pubitemid 40271133)
28. Pocock SJ, Elbourne DR: Randomized trials or observational tribulations? N Engl J Med 342:1907-1909, 2000
29. Abraham EP, Chain CM, Fletcher HW: Further observations on penicillin. Lancet 2:177-188, 1941
30. Ligon BL: Penicillin: Its discovery and early development. Semin Pediatr Infect Dis 15:52-57, 2004
31. Sacks MS, Bradford GT, Schoenbach EB: The response of acute leukemia to the administration of the folic acid antagonists, aminopterin and a-methopterin: Report of 14 cases. Ann Intern Med 32:80-115, 1950
32. Cohen MH, Williams G, Johnson JR, et al: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942, 2002 (Pubitemid 34520420)
33. Hartz A, Benson K, Glaser J, et al: Assessing observational studies of spinal fusion and chemonucleolysis. Spine 28:2268-2275, 2003 (Pubitemid 37214704)
34. Hartz A, Bentler S, Charlton M, et al: Assessing observational studies of medical treatments. Emerg Themes Epidemiol 2:8, 2005
35. Fine RL, Fogelman DR, Schreibman SM, et al: The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis. Cancer Chemother Pharmacol 61: 167-175, 2008 (Pubitemid 47512638)
36. Fine RL, Sherman WH, Moorer M, et al: Prospective phase II trial of GTX chemotherapy for metastatic pancreatic cancer. J Clin Oncol 27:232s, 2009 (suppl; abstr 4623)
37. Ko AH, Tempero MA: Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw 3:627-636, 2005 (Pubitemid 44265411)
38. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
39. Cunningham D, Chau I, Stocken D, et al: Phase III randomised comparison of gemictabine (GEM) versus gemcitabine plus capecitabine (GEMCAP) in patients with advanced pancreatic cancer. Eur J Cancer 4:1-14, 2005 (suppl)
40. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
41. Ries L, Eisner M, Kosary C, et al: Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975-2002 (of November 2004 SEER data submission). Bethesda, MD, 2005. http://seer-.cancer.gov/csr/1975-2002/
42. Poplin E, Levy D, Berlin J, et al: Phase III trial of gemcitabine (30-minute infusion), versus gemcitabine (fixed-dose-rate infusion (FSR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006 (abstr E6201)
43. Nieto J, Grossbard ML, Kozuch P: Metastatic pancreatic cancer 2008: Is the glass less empty? Oncologist 13:562-576, 2008
44. Dagenais S, Tricco AC, Bian ZX, et al: Critical appraisal of clinical studies in Chinese herbal medicine. Zhong Xi Yi Jie He Xue Bao 4:455-466, 2006
45. Allendorf J, Ippagunta N, Emond J: Management of liver metastases: New horizons for biologically based therapy. J Surg Res 117:144-153, 2004 (Pubitemid 38317220)